Company Performance Metrics
f5 Therapeutics' platform is expanding the scope of degradable targets in the Targeted Protein Degradation space. Our methods allow access to the abundance of undiscovered neosubstrates available for degradation with potential in multiple indications. We identify these new targets in context with cellular assays allowing us to fully realize
the wide class of neosubstrates afforded by cereblon. Multiple new targets we have discovered are currently not being pursued by other degrader companies. NExMods™ have demonstrated in vitro POC across five therapeutic areas (immuno-oncology, Wnt-driven cancers, auto-immune disease, NASH, liver fibrosis) and demonstrated 100X cereblon binding potency versus known clinical IMiDs. f5 Therapeutics is exploring their immuno-oncology and oncology libraries as Degrader Antibody Conjugates (payloads for targeted mAb).
